Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
GENB Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
36.48%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Generate Biomedicines, Inc.
Market Cap
$1.77B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.75B
Return on Equity (ROE)
-5.30%
TTM Avg
-6.97%
3Y Avg
-4.32%
5Y Avg
-7.48%
Market Cap
$1.74B
Return on Equity (ROE)
-43.94%
TTM Avg
-43.41%
3Y Avg
-41.23%
5Y Avg
-29.16%
Market Cap
$1.74B
Return on Equity (ROE)
-49.19%
TTM Avg
-59.18%
3Y Avg
-54.84%
5Y Avg
-44.72%
Market Cap
$1.74B
Return on Equity (ROE)
N/A
TTM Avg
94.61%
3Y Avg
224.41%
5Y Avg
83.14%
Market Cap
$1.74B
Return on Equity (ROE)
15.35%
TTM Avg
-64.31%
3Y Avg
-71.44%
5Y Avg
-70.74%
Market Cap
$1.81B
Return on Equity (ROE)
-32.46%
TTM Avg
-24.39%
3Y Avg
-19.07%
5Y Avg
-12.85%
Market Cap
$1.81B
Return on Equity (ROE)
15.62%
TTM Avg
13.87%
3Y Avg
11.38%
5Y Avg
11.40%
Market Cap
$1.73B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.77B | N/A | 36.48% | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -5.30% | -6.97% | -4.32% | -7.48% |
| Novocure Ltd (NVCR)vs › | $1.74B | -43.94% | -43.41% | -41.23% | -29.16% |
| Absci Corporation (ABSI)vs › | $1.74B | -49.19% | -59.18% | -54.84% | -44.72% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | N/A | 94.61% | 224.41% | 83.14% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 15.35% | -64.31% | -71.44% | -70.74% |
| Xencor, Inc. (XNCR)vs › | $1.81B | -32.46% | -24.39% | -19.07% | -12.85% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 15.62% | 13.87% | 11.38% | 11.40% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -54.96% | -60.50% | -51.30% | -42.73% |
| Azenta, Inc. (AZTA)vs › | $1.81B | -8.14% | -6.28% | -6.47% | -2.03% |
ROE
N/A
ROA
-61.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 32.98% |
| 2024-12-31 | 39.99% |
